Difference between revisions of "List of chemotherapy regimens"
Jump to navigation
Jump to search
(→A) |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
| − | |||
==0-9== | ==0-9== | ||
==A== | ==A== | ||
| − | [ | + | *[[Hodgkin_lymphoma#ABVD|ABVD (Hodgkin Lymphoma)]] |
| + | *[[Hodgkin_lymphoma#ABVD_3|ABVD (Lymphocyte predominant Hodgkin Lymphoma)]] | ||
==B== | ==B== | ||
| + | *[[Hodgkin_lymphoma#BEACOPP|BEACOPP (Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#Escalated_Dose_BEACOPP|Escalated Dose BEACOPP (Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#Mini-BEAM|BEAM (mini) (Hodgkin Lymphoma)]] | ||
| + | |||
==C== | ==C== | ||
| + | *[[Hodgkin_lymphoma#ChIVPP|ChIVPP (Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#CHOP|CHOP (Lymphocyte predominant Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#C-MOPP.2FABV|C-MOPP/ABV (Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#C-MOPP.2FABVD|C-MOPP/ABVD (Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#CVP|CVP (Lymphocyte predominant Hodgkin Lymphoma)]] | ||
| + | |||
==D== | ==D== | ||
| + | *[[Hodgkin_lymphoma#DHAP|DHAP (Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#DHAP_-_time_intensified|DHAP - time intensified (Hodgkin Lymphoma)]] | ||
==E== | ==E== | ||
| + | *[[Hodgkin_lymphoma#EPOCH|EPOCH (Lymphocyte predominant Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#ESHAP|ESHAP (Hodgkin Lymphoma)]] | ||
| + | |||
==F== | ==F== | ||
==G== | ==G== | ||
| + | *[[Hodgkin_lymphoma#GCD|GCD (Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#GVD|GVD (Hodgkin Lymphoma)]] | ||
| + | |||
==H== | ==H== | ||
==I== | ==I== | ||
| + | *[[Hodgkin_lymphoma#ICE|ICE (Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#IGEV|IGEV (Hodgkin Lymphoma)]] | ||
| + | |||
==J== | ==J== | ||
==K== | ==K== | ||
==L== | ==L== | ||
==M== | ==M== | ||
| + | *[[Hodgkin_lymphoma#MINE|MINE (Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#Mini-BEAM|Mini-BEAM (Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#MOPP|MOPP (Hodgkin Lymphoma)]] | ||
==N== | ==N== | ||
==O== | ==O== | ||
| Line 23: | Line 45: | ||
==Q== | ==Q== | ||
==R== | ==R== | ||
| + | *[[Hodgkin_lymphoma#R-CHOP|R-CHOP (Lymphocyte predominant Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#R-CVP|R-CVP (Lymphocyte predominant Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#R-EPOCH|R-EPOCH (Lymphocyte predominant Hodgkin Lymphoma)]] | ||
| + | *[[Hodgkin_lymphoma#Single_agent_Rituximab_.28Rituxan.29|Rituxan (Rituximab) - single agent (Lymphocyte predominant Hodgkin Lymphoma)]] | ||
==S== | ==S== | ||
| + | *[[Hodgkin_lymphoma#Stanford_V|Stanford V (Hodgkin Lymphoma)]] | ||
==T== | ==T== | ||
==U== | ==U== | ||
Revision as of 05:46, 11 December 2011
0-9
A
B
C
- ChIVPP (Hodgkin Lymphoma)
- CHOP (Lymphocyte predominant Hodgkin Lymphoma)
- C-MOPP/ABV (Hodgkin Lymphoma)
- C-MOPP/ABVD (Hodgkin Lymphoma)
- CVP (Lymphocyte predominant Hodgkin Lymphoma)
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
- R-CHOP (Lymphocyte predominant Hodgkin Lymphoma)
- R-CVP (Lymphocyte predominant Hodgkin Lymphoma)
- R-EPOCH (Lymphocyte predominant Hodgkin Lymphoma)
- Rituxan (Rituximab) - single agent (Lymphocyte predominant Hodgkin Lymphoma)